Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol

Next Previous
Search
Trial Profile

XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms XIENCE V Japan
  • Sponsors Abbott Laboratories; Abbott Vascular

    • Most Recent Events

    • 18 Mar 2019 Results of a pooled analysis of the four XIENCE Post-Approval Trials assessing the impact of Renal Function in Patients With High Bleeding Risk Who Underwent Percutaneous Coronary Intervention With XIENCE, presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 25 Sep 2018 Results of a pooled analysis from post-approval registries XIENCE V USA, XIENCE V Japan, and XIENCE V India (n=8020) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 03 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top